Greenwich LifeSciences (Nasdaq: GLSI) has extended its insider share lock-up through September 30, 2026—an extraordinary 6-year commitment aimed at aligning leadership with long-term shareholders as it advances its Phase III FLAMINGO-01 breast cancer trial. Early data from the trial show a promising ~80% reduction in breast cancer recurrence rate post-immunization, reinforcing the potential of GLSI-100 as a breakthrough immunotherapy.

OBOOK Holdings (Nasdaq: OWLS), operating as the OwlTing Group, has entered the execution phase of its $10 million share repurchase program, reinforcing its confidence in the company’s fundamentals and strategic outlook. Backed by strong cash flow and a growing global footprint in stablecoin settlement and blockchain-based payments, the move reflects OwlTing’s focus on capital efficiency and enhancing long-term shareholder value.

FibroBiologics (Nasdaq: FBLG) has filed an IND with the FDA to initiate Phase 1/2 trials of CYPS317, a novel allogeneic fibroblast spheroid therapy for moderate to severe psoriasis. Backed by strong preclinical data showing superior durability and immune modulation over current biologics, CYPS317 represents a major step toward redefining treatment in a $20B+ global psoriasis market.

A peer-reviewed study sponsored by 60 Degrees Pharmaceuticals (Nasdaq: SXTP) found Babesia infection in 24% of chronic fatigue patients—supporting the theory that this tick-borne parasite may prolong recovery from chronic illness. The findings strengthen the rationale for the ongoing B-Free Study evaluating ARAKODA® (tafenoquine) as a potential therapy for chronic babesiosis, a rising but underdiagnosed disease affecting tens of thousands annually.